University of Glasgow-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2020

  1. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

    The Lancet, Vol. 396, Núm. 10264, pp. 1745-1757

2017

  1. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210

  2. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150

  3. Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: A novel analysis from the global burden of disease study 2015

    The Lancet, Vol. 390, Núm. 10091, pp. 231-266

2015

  1. Serumuric acidandthe riskof cardiovascular and renal disease

    Journal of Hypertension, Vol. 33, Núm. 9, pp. 1729-1741

2014

  1. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia

    BMJ Open, Vol. 4, Núm. 7

  2. Up-titration of allopurinol in patients with gout

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 1, pp. 25-30